Haemonetics (HAE)

Executive Summary

Haemonetics is a global medical technology leader specializing in blood management, plasma collection, and surgical blood salvage solutions. The company's core products include the NexSys PCS plasmapheresis system, TEG 6s hemostasis analyzer, and VascuSafe autotransfusion system. Haemonetics has been successfully transitioning to a software-enabled subscription model, enhancing recurring revenue and customer stickiness. In fiscal 2025, the company reported revenue of approximately $1.3 billion, driven by strong performance in its Plasma and Hospital segments. The Plasma division benefits from increasing demand for source plasma used in therapies, while the Hospital segment gains traction through expanded adoption of the TEG 6s for point-of-care coagulation testing. Haemonetics maintains a solid competitive position with proprietary technology and a global footprint, though growth is tempered by market maturation and pricing pressures. The company continues to invest in R&D to expand its product portfolio and address unmet needs in transfusion medicine and hemostasis management.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval for Next-Generation Platelet Additive Solution (PAS)70% success
• Q1 2027NexSys PCS Launch in Japan60% success
• Q2 2026U.S. Clearance for Whole Blood Hemostasis Test (TEG 6s WB)80% success